
    
      Subjects will be randomized in a 2:1 ratio to receive a once-weekly subcutaneous treatment
      and an additional loading dose on Study Day 3 with either IONIS-AGT-LRx or placebo for 6
      weeks.

      All subjects will complete a 13-week Post-Treatment Period.
    
  